Incyte (INCY) Stock Forecast & Price Target

Incyte's robust growth trajectory is supported by an expected high-single-digit increase in prescriptions and mid-single-digit sales growth, driven by the strong demand for its leading drug, Jakafi, which saw an 11% year-over-year increase in paid demand. The company's net product revenues consistently exceeded market expectations, highlighting a seventh consecutive revenue beat, with significant contributions from Opzelura, which achieved net sales of $207 million, reflecting a 28% year-over-year growth. Additionally, the firm's overall net product revenue guidance for the fiscal year, projected between $4,770 million and $4,940 million, underscores a healthy growth outlook bolstered by strong performances across both its oncology and dermatology product lines.

The excerpts indicate a negative outlook on Incyte's stock primarily due to the substantial revenue risk associated with Jakafi, which is poised for a loss of exclusivity in late FY28, representing nearly $4 billion at risk. Despite incremental clinical advancements and pipeline successes, the overall total addressable market (TAM) does not suffice to compensate for this projected revenue shortfall, resulting in a stagnant trading range for Incyte shares. Furthermore, significant concerns regarding the slow uptake of new therapies, potential approval delays, and the risk of equity dilution elevate the uncertainty surrounding the company's future financial performance.